Literature DB >> 9745886

Severe thalassaemia intermedia: clinical problems in the absence of hypertransfusion.

N Mohamed1, N Jackson.   

Abstract

In many of the parts of the world where thalassaemia is common, the blood supply is inadequate or unsafe, and desferrioxamine is too expensive for routine use. We classify some patients as having 'severe thalassaemia intermedia', i.e. those with moderately severe thalassaemia who can survive without regular transfusions, but who are at risk of many complications which are reviewed here. These include bone deformity and fractures, extramedullary haemopoietic tumours, leg ulcers, autoimmune haemolysis and, especially after splenectomy, thromboembolism and infection. An increase in the quality and safety of the blood supply, and a cheaper and/or oral iron chelator, would enable more of these patients to be treated as thalassaemia major and have improved survival and quality of life.

Entities:  

Mesh:

Year:  1998        PMID: 9745886     DOI: 10.1016/s0268-960x(98)90014-5

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  4 in total

1.  Association between bone mineral density and erythropoiesis in Thai children and adolescents with thalassemia syndromes.

Authors:  Pat Mahachoklertwattana; Pensri Pootrakul; Ampaiwan Chuansumrit; Lulin Choubtum; Arporn Sriphrapradang; Rojana Sirisriro; Rajata Rajatanavin
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

2.  Anesthetic management of a patient with beta-thalassemia intermedia undergoing splenectomy: a case report.

Authors:  Takeshi Kitoh; Satoshi Tanaka; Koichi Ono; Joe Hasegawa; Tetsutaro Otagiri
Journal:  J Anesth       Date:  2005       Impact factor: 2.078

Review 3.  The transfusion management of beta thalassemia in the United States.

Authors:  Ashutosh Lal; Trisha Wong; Siobán Keel; Monica Pagano; Jong Chung; Aditi Kamdar; Latha Rao; Alan Ikeda; Geetha Puthenveetil; Sanjay Shah; Jennifer Yu; Elliott Vichinsky
Journal:  Transfusion       Date:  2021-08-28       Impact factor: 3.337

4.  Gene expression of the liver in response to chronic hypoxia.

Authors:  Monica M Baze; Karen Schlauch; Jack P Hayes
Journal:  Physiol Genomics       Date:  2010-01-26       Impact factor: 3.107

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.